Analysts Set Shattuck Labs, Inc. (NASDAQ:STTK) PT at $7.50

Shattuck Labs, Inc. (NASDAQ:STTK - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the seven analysts that are covering the firm, Marketbeat.com reports. Four investment analysts have rated the stock with a hold recommendation, one has given a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $7.50.

A number of research analysts have issued reports on the stock. Leerink Partners initiated coverage on shares of Shattuck Labs in a research note on Monday. They set an "outperform" rating and a $4.00 target price for the company. Leerink Partnrs upgraded Shattuck Labs to a "strong-buy" rating in a research report on Monday.

Institutional Trading of Shattuck Labs

Institutional investors have recently made changes to their positions in the stock. Zacks Investment Management bought a new stake in Shattuck Labs during the fourth quarter worth approximately $25,000. Virtu Financial LLC acquired a new position in shares of Shattuck Labs during the 4th quarter valued at $30,000. Atom Investors LP bought a new stake in shares of Shattuck Labs in the 3rd quarter worth $35,000. Readystate Asset Management LP acquired a new stake in shares of Shattuck Labs in the third quarter valued at $39,000. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in shares of Shattuck Labs in the fourth quarter valued at $45,000. 58.74% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Shattuck Labs Stock Performance

Shares of STTK traded up $0.04 during midday trading on Monday, hitting $1.20. 186,977 shares of the stock traded hands, compared to its average volume of 379,508. The business's 50 day moving average price is $1.24 and its two-hundred day moving average price is $1.59. The firm has a market capitalization of $57.29 million, a PE ratio of -0.78 and a beta of 1.66. Shattuck Labs has a 1-year low of $0.94 and a 1-year high of $11.76.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.